MariMed Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- MariMed Inc. (MRMD), a multi-state cannabis operator, develops, owns, and manages state-licensed facilities for the cultivation, production, and retail dispensing of medical and adult-use cannabis products across the United States; its award-winning portfolio includes Nature’s Heritage brand flower, vapes, and concentrates; Betty’s Eddies fruit chews for sleep, pain, and stress relief; Emack & Bolio's cannabis-infused ice creams; Bubby’s Baked soft chewy baked goods and hot chocolate mix; Vibations hydrating drink mixes; and InHouse flower, vapes, and edibles, with additional revenue from real estate rentals, supply procurement, management fees, and brand licensing. Founded in 2011 and headquartered in Norwood, Massachusetts, the company operates cultivation, processing, and dispensary facilities primarily in Delaware, Illinois, Maryland, Massachusetts, and other states, targeting wellness-focused medical patients and adult-use consumers. Recent developments include the March 2025 completion of its acquisition of First State Compassion Center, Delaware's leading cannabis operator with cultivation, processing, and two dispensaries; expansion of Betty’s Eddies distribution to Maine in July 2025; a July 2025 managed services and licensing agreement with TILT Holdings for a Pennsylvania cultivation and processing facility; an October 2025 licensing deal with Farm 2 Hand to introduce edibles in New York starting in 2026; exit from the Missouri market in October 2025; and November 2025 agreements to launch hemp-derived THC products, beginning with Vibations in Rhode Island by early 2026.
MariMed Inc. (MRMD) Q1 2026 Earnings Call Transcript
MariMed Inc. (MRMD) Reports Q1 Loss, Beats Revenue Estimates
MariMed Reports First Quarter 2026 Earnings
MariMed Reports First Quarter 2026 Earnings
MariMed Announces First Quarter 2026 Earnings Date
MariMed Inc. (MRMD) Q4 2025 Earnings Call Transcript
MariMed Reports Fourth Quarter and Full Year 2025 Earnings
MariMed Extends Series B Preferred Stock Obligation Through 2031, Strengthening Capital Structure
MariMed Announces Fourth Quarter and Full Year 2025 Earnings Date
MariMed (OTCMKTS:MRMD) versus Brainsway (NASDAQ:BWAY) Head-To-Head Review
MariMed Statement on Historic Rescheduling of Cannabis
Veterans Healing Journey Becomes Soundtrack of Thrive Dispensaries
MariMed's Betty's Eddies™ Introduces New Limited-Edition Winter Seasonal Cranberry Orange Fruit Chew, Bundle Up Betty's
MariMed Inc. (MRMD) Q3 2025 Earnings Call Transcript
MariMed Inc. (MRMD) Reports Q3 Loss, Misses Revenue Estimates
MariMed Reports Third Quarter 2025 Earnings
MariMed To Launch Hemp-Derived THC Products, Introducing Its Top-Selling Brands to New Markets and Customers
MariMed Inc. (MRMD) Upgraded to Strong Buy: What Does It Mean for the Stock?
MariMed's InHouse Brand Again Supports Veterans Facing Housing Challenges With Second Annual Help on the Homefront Campaign
MariMed Announces Third Quarter 2025 Earnings Date